SC 13G - Envoy Medical, Inc. (0001840877) (Subject)

SC 13G - Envoy Medical, Inc. (0001840877) (Subject)

4 - Envoy Medical, Inc. (0001840877) (Issuer)

WHITE BEAR LAKE, Minn., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. ("Envoy Medical") (NASDAQ:COCH), a revolutionary hearing health company focused on fully implanted hearing devices, today announces its corporate and financial results for the third quarter ended September 30, 2024, as well as other subsequent events. "The progress and accomplishments of late have been extremely important to Envoy Medical as they have set the stage for us to demonstrate the value of fully implanted hearing devices. First, we have received FDA's approval to start our pivotal trial of the Acclaim® fully implanted cochlear implant ("Acclaim CI"). Second, we continue to make tremendous

Study in Otology & Neurotology outlines early experiences and potential benefits of breakthrough fully implanted cochlear implant WHITE BEAR LAKE, Minnesota , Nov. 12, 2024 (GLOBE NEWSWIRE) --  Envoy Medical®, Inc. ("Envoy Medical") (NASDAQ: "COCH"), a hearing health company focused on fully implanted hearing systems, today announces a peer-reviewed publication in Otology & Neurotology, discussing early experiences with and highlighting potential benefits of the Company's investigational fully implanted Acclaim® Cochlear Implant (Acclaim CI). The paper, titled, "Early Hearing Outcomes and Audiological Experiences with a Novel Fully Implanted Cochlear Implant," discusses the initial result

WHITE BEAR LAKE, Minnesota, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. ("Envoy Medical") (NASDAQ: "COCH"), a hearing health company focused on fully implanted hearing systems, today announces that the European Patent Office has granted the Company Patent No. 3858425, titled," Implantable Modular Cochlear Implant System with Communication System and Network." The patent relates to a modular cochlear implant system configured to receive input signals from an implantable source and a wireless receiving device and output a stimulation signal based on the received input signals and a programmable mixing ratio representative of the relative contributions of the input signals to th

The Acclaim® Fully Implanted Cochlear Implant is differentiated from existing cochlear implants and may offer new option for hearing loss patients WHITE BEAR LAKE, Minnesota, Nov. 01, 2024 (GLOBE NEWSWIRE) --  Envoy Medical®, Inc. ("Envoy Medical") (NASDAQ: "COCH"), a hearing health company focused on fully implanted hearing systems, today announces that its Investigational Device Exemption (IDE) application for its pivotal study of the Acclaim® Fully Implanted Cochlear Implant has been approved by the U.S. Food and Drug Administration (FDA). The Acclaim® technology includes an implanted sensor designed to leverage the natural anatomy of the ear to capture sound, making it different from

Twelve Members of the Independence Through Enhancement of Medicare and Medicaid (ITEM) Coalition Sign Letter to CMS Seeking Clarification of Prior Decision Making and Action to Bring Novel Hearing Technology to Medicare Beneficiaries WHITE BEAR LAKE, Minnesota, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. ("Envoy Medical") (NASDAQ: "COCH"), a hearing health company focused on fully implanted hearing systems, expresses gratitude to the Independence Through Enhancement of Medicare and Medicaid ("ITEM") Coalition and the twelve ITEM member signatories for sending a strong letter to CMS supporting a reconsideration of the benefit category for fully implanted active middle ear he

WHITE BEAR LAKE, Minnesota, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. ("Envoy Medical") (NASDAQ: "COCH"), a hearing health company focused on fully implanted hearing systems, today announced that David R. Wells, Chief Financial Officer, will present a corporate overview at the LD Micro Main Event XVII. The conference is being held on October 28 – 30, 2024 at the Luxe Sunset Boulevard Hotel in Los Angeles. Event:                                                  LD Micro Main Event XVII Presentation Date:                            Tuesday, October 29, 2024 Time:                                                   12:00 PM Pacific Time Register

The Esteem® device is the only totally implantable active middle ear implant with FDA Approval, allowing the Company to be the first to capitalize on the new codes WHITE BEAR LAKE, Minnesota, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Envoy Medical, Inc. (NASDAQ:COCH), a market leader in fully implanted hearing devices, today announced that the American Medical Association (AMA) Current Procedural Terminology (CPT) Editorial Panel has approved five Category III CPT codes for totally implantable active middle ear implants (AMEI), a crucial development for the Company's already FDA-approved Esteem® product. This marks the first time that there will be CPT codes for totally implantable active midd

Performance of COCH after de-SPAC sixty day "washout" period among leaders in peer group and Envoy Medical bullish on its long-term strategy WHITE BEAR LAKE, Minnesota , Oct. 01, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. ("Envoy Medical") (NASDAQ: "COCH"), a hearing health company focused on fully implanted hearing systems, today commemorates its one-year anniversary trading as a public company. On September 29, 2023, the formerly private Envoy Medical merged with Anzu Special Purpose Acquisition Corp I, creating the now publicly traded Envoy Medical. COCH began trading on the Nasdaq Capital Market on October 2, 2023.   "Over the last year, we have made significant progress t

During "The Claman Countdown," the billionaire investor and entrepreneur noted how hearing aid modes in next-gen wireless earbuds can work with Envoy Medical's fully implanted hearing devices WHITE BEAR LAKE, Minnesota, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. ("Envoy Medical") (Nasdaq: "COCH"), a hearing health company focused on fully implanted hearing systems, today highlights an interview with key investor Glen Taylor on Fox Business News "The Claman Countdown" in which he commented on the news that Apple's new AirPods Pro 2 can be used as hearing aids.    In the interview, Mr. Taylor was asked whether he was worried about Apple entering the hearing technology

Growing Portfolio of Patents Further Advances the Company's Mission to Develop Fully Implanted Devices for Those Suffering from Significant Hearing Loss WHITE BEAR LAKE, Minnesota, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. ("Envoy Medical") (NASDAQ: "COCH"), a hearing health company focused on fully implanted hearing systems, today announces it has been awarded another patent from the US Patent & Trademark Office for its fully implanted devices. On September 3rd, the Company was issued Patent No. 12,081,061, "Recharge System for Implantable Battery," which relates to predicting a cumulative thermal dose associated with charging an implantable rechargeable energy storage de

4 - Envoy Medical, Inc. (0001840877) (Issuer)

4 - Envoy Medical, Inc. (0001840877) (Issuer)

4 - Envoy Medical, Inc. (0001840877) (Issuer)

4 - Envoy Medical, Inc. (0001840877) (Issuer)

4 - Envoy Medical, Inc. (0001840877) (Issuer)

4 - Envoy Medical, Inc. (0001840877) (Issuer)

4 - Envoy Medical, Inc. (0001840877) (Issuer)

3 - Envoy Medical, Inc. (0001840877) (Issuer)

4 - Envoy Medical, Inc. (0001840877) (Issuer)

Ascendiant Capital Markets initiated coverage of Envoy Medical with a rating of Buy and set a new price target of $8.50

WHITE BEAR LAKE, Minn., June 11, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. ("Envoy Medical") (NASDAQ:COCH) today announced the appointment of Michael Crowe to the Envoy Medical Board of Directors effective June 7, 2024. Envoy Medical is currently sponsoring an Early Feasibility Study at Mayo Clinic in Rochester, Minnesota for its investigational fully implanted Acclaim® Cochlear Implant. Envoy Medical expects to begin a larger pivotal clinical study for its device later in 2024. Mr. Crowe, who received his BS in Electrical Engineering from the University of Louisville and his MBA from Duke University, has decades of experience helping companies grow operations quickly and efficiently

Analyst Hosted Event to Feature Comprehensive Discussion of Envoy Medical's Products, Interviews with Two Study Investigators and Key Opinion Leaders in Cochlear Implants WHITE BEAR LAKE, Minnesota, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. ("Envoy Medical") (NASDAQ: "COCH"), a revolutionary hearing health company focused on fully implanted hearing systems, today announced that it will host a fireside chat event on Thursday December 7, 2023 beginning at noon Central Time. The event will be hosted by a covering research analyst and feature interactive Q&A with Brent T. Lucas, Chief Executive Officer, and David R. Wells, Chief Financial Officer. Additionally, the Company

8-K - Envoy Medical, Inc. (0001840877) (Filer)

424B3 - Envoy Medical, Inc. (0001840877) (Filer)

424B3 - Envoy Medical, Inc. (0001840877) (Filer)

10-Q - Envoy Medical, Inc. (0001840877) (Filer)

8-K - Envoy Medical, Inc. (0001840877) (Filer)

EFFECT - Envoy Medical, Inc. (0001840877) (Filer)

DEFA14A - Envoy Medical, Inc. (0001840877) (Filer)

DEF 14A - Envoy Medical, Inc. (0001840877) (Filer)

S-3 - Envoy Medical, Inc. (0001840877) (Filer)

8-K - Envoy Medical, Inc. (0001840877) (Filer)

Ascendiant Capital analyst Edward Woo initiates coverage on Envoy Medical (NASDAQ:COCH) with a Buy rating and announces Price Target of $8.5.

Envoy Medical in Position to Leverage its Sensor Technology WHITE BEAR LAKE, MN, June 05, 2024 (GLOBE NEWSWIRE) --  Envoy Medical®, Inc. ("Envoy Medical") (NASDAQ:COCH) today highlighted a recently published article in the Current Otorhinolaryngology Reports. The article, titled, "Fully Implanted Cochlear Implants," was authored by Dr. Eric Babajanian, Dr. James Dornhoffer, and Dr. Colin Driscoll from Mayo Clinic in Rochester, Minnesota. Authors describe it as a review of the current state of fully implanted cochlear implants, including some of the challenges, limitations and breakthroughs.

Gainers Biodexa Pharmaceuticals (NASDAQ:BDRX) shares increased by 67.7% to $2.13 during Tuesday's pre-market session. The market value of their outstanding shares is at $9.3 million. Durect (NASDAQ:DRRX) stock rose 23.07% to $1.28. The market value of their outstanding shares is at $39.7 million. Larimar Therapeutics (NASDAQ:LRMR) stock rose 17.33% to $8.53. The market value of their outstanding shares is at $544.2 million. Tevogen Bio Holdings (NASDAQ:TVGN) shares moved upwards by 16.64% to $0.91. The market value of their outstanding shares is at $149.7 million. Envoy Medical (NASDAQ:COCH) shares rose 14.81% to $3.72. The company's market cap stands at $72.9 million. As per the news,

Envoy Medical (NASDAQ:COCH) reported quarterly losses of $(0.32) per share. The company reported quarterly sales of $59.00 thousand which missed the analyst consensus estimate of $100.00 thousand by 41.00 percent.

Gainers Repare Therapeutics (NASDAQ:RPTX) shares rose 34.1% to $4.4 during Wednesday's pre-market session. The company's market cap stands at $186.7 million. The company's, Q1 earnings came out yesterday. Enveric Biosciences (NASDAQ:ENVB) shares increased by 16.85% to $1.04. The company's market cap stands at $7.5 million. Clover Health Investments (NASDAQ:CLOV) stock increased by 16.21% to $0.86. The company's market cap stands at $426.3 million. As per the press release, Q1 earnings came out yesterday. Envoy Medical (NASDAQ:COCH) stock rose 13.88% to $3.28. The company's market cap stands at $64.2 million. Myriad Genetics (NASDAQ:MYGN) stock moved upwards by 13.75% to $22.5. The marke

Gainers FibroGen (NASDAQ:FGEN) shares rose 37.1% to $1.59 during Tuesday's pre-market session. The market value of their outstanding shares is at $158.1 million. The company's, Q1 earnings came out yesterday. Envoy Medical (NASDAQ:COCH) stock moved upwards by 23.54% to $4.25. The company's market cap stands at $83.2 million. iSpecimen (NASDAQ:ISPC) shares rose 21.18% to $0.33. The company's market cap stands at $3.0 million. The company's, Q1 earnings came out today. NovaBay Pharmaceuticals (AMEX:NBY) shares moved upwards by 20.87% to $0.11. The company's market cap stands at $3.9 million. GT Biopharma (NASDAQ:GTBP) shares rose 19.25% to $3.84. The market value of their outstanding shar

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) fell sharply during Monday’s session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic disorder causing developmental disabilities and nerve-related symptoms. Ultragenyx Pharmaceutical shares dipped 9.4% to $42.46 on Monday. Here are some other stocks moving in today's mid-day session. Gainers Soligenix, Inc. (NASDAQ:SNGX) shares surged 71.5% to $0.6679 after the company announced that it was granted orphan drug designation to the active ingredient in MarVax for the prevention and post-exposure prophylaxis against MARV infection by the FDA. Longeveron Inc. (NASDAQ:LGVN) su